| Market Cap | 125.91K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -260.51k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -48.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -69.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -89.00% |
| Recommedations | - | Quick Ratio | 0.00 | Shares Outstanding | 78.70M | 52W Low Chg | 45.00% |
| Insider Own | - | ROA | -209.57% | Shares Float | 63.94M | Beta | -2.07 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.00160 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 27,375 | Target Price | - |
| Oper. Margin | - | Earnings Date | - | Volume | 2,000 | Change | 0.00% |
QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon.